Status:
COMPLETED
Subfoveal Choroidal Thickness and Visual Acuity After Intravitreal Injection of Ranibizumab in Diabetic Retinopathy
Lead Sponsor:
Egyptian Biomedical Research Network
Conditions:
Subfoveal Choroidal Thickness
Intravitreal
Eligibility:
All Genders
50-70 years
Phase:
NA
Brief Summary
The aim of this study is to compare subfoveal choroidal thickness (SFCT) and the visual status before and after intravitreal injection of ranibizumab in diabetic macular edema (DME) with the use of 3D...
Detailed Description
Diabetes is a metabolic disorder affecting the ocular vasculature. Although the principal posterior segment changes in diabetes usually occur in the retinal vasculature, additional changes are also ob...
Eligibility Criteria
Inclusion
- Age from 50 to 70 years.
- Both sexes.
- Patients suffering from diabetic macular edema (DME).
Exclusion
- High myopia more than 6 diopters.
- previous injections or retinal surgery.
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06173245
Start Date
February 1 2021
End Date
February 1 2023
Last Update
December 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Al-Azhar University
Asyut, Egypt